SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?


To: Charles Tutt who wrote (386)8/1/2000 5:49:59 PM
From: Elmer  Read Replies (2) | Respond to of 810
 
You are right. The ownership changed hands and probably most of the buyers are looking for a fast buck. A bad sign.

Occasionally, a company's stock will go up 40% or more and repeat that feat on following two trading days. Rambus did it about two years ago. What may give the longs some support is the lack of coverage. If a couple analysts look over the Nature Article and begin coverage saying its a "must own", the price won't revisit $10.

If you look at a long term chart, the stock price is about the same as when it went public in May of 1996.



To: Charles Tutt who wrote (386)8/1/2000 6:17:12 PM
From: Elmer  Respond to of 810
 
Charles,
One other point. The market cap is miniscule. If you compare it with a bunch of biotechs that have gone public this year, including Tularik, Exelilis, Illumina, Diversa and Maxagen, it's very cheap even after today's pop.